Bailard’s Nuvation Bio NUVB Stock Holding History

Bailard’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,000	Closed	-$116K	–	827
2026 Q1	$116K	Buy	+27,000	New	+$150K	﹤0.01%	720
2021 Q4	–	Sell	-29,100	Closed	-$289K	–	764
2021 Q3	$289K	Hold	29,100	–	–	0.01%	541
2021 Q2	$271K	Buy	+29,100	New	+$332K	0.01%	574

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bailard's NUVB Position: Q2 2026 in Review

Bailard sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 27,000 shares — an estimated $116K sold.

Bailard first reported a position in NUVB in Q2 2021 and held it in 3 quarters. The position peaked at $289K in Q3 2021. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

Bailard reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
Bailard sold 27,000 Nuvation Bio shares in Q2 2026, an estimated $116K.
Bailard first reported a position in Nuvation Bio in Q2 2021 and held it in 3 quarters.
Bailard's Nuvation Bio position peaked at $289K in Q3 2021.
244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.